GILD · Gilead Sciences, Inc. · Investor Relations

$168.08 +0.13 (+0.08%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript

S&P 500 member Nasdaq-100 member Russell 1000 member Rebalance outlook locked

Market Cap

$208.48B

1.24B

Volume · Nov 13 3.64M Avg daily vol (3M) 5.96M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date	Event	Type
2026-11-17 10:00 UTC	UBS Global Biopharma Conference	Conference
2026-11-17 14:30 UTC	Jefferies Global Healthcare Conference	Conference
2026-11-17 14:30 UTC	Jefferies Global Healthcare Conference in London	Conference
2026-12-01 16:00 UTC	Citi’s Global Healthcare Conference	Conference
2026-12-02 16:40 UTC	Annual Evercore Healthcare Conference	Conference

Recent news

Date	Headline
2026-11-12	Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®
2026-11-06	New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
2026-11-05	Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
2026-11-04	Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
2026-11-02	Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
2026-10-30	Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
2026-10-29	Gilead Sciences Announces Third Quarter 2026 Financial Results
2026-10-22	Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
2026-10-22	Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
2026-10-19	Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
2026-10-15	Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
2026-09-16	Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
2026-09-15	Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
2026-09-08	Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
2026-08-27	U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
2026-08-26	Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
2026-08-24	European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
2026-08-05	CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
2026-08-04	Gilead Sciences Announces Second Quarter 2026 Financial Results
2026-07-24	CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
2026-07-21	Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
2026-07-21	Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
2026-07-21	Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
2026-06-24	U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
2026-06-23	European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

Past events

Date	Event	Type
2026-11-10	Wolfe Research Healthcare Conference	Conference
2026-11-10	HIV Glasgow 2026	Conference
2026-10-29	Gilead Sciences Q3 2026 Earnings Conference Call	Earnings call
2026-09-15	Morgan Stanley Global Healthcare Conference	Conference
2026-09-10	Cantor Global Healthcare Conference	Conference
2026-09-09	Wells Fargo Annual Healthcare Conference	Conference
2026-08-04	Gilead Sciences Q2 2026 Earnings Conference Call	Earnings call
2026-06-09	Goldman Sachs Annual Global Healthcare Conference	Conference
2026-05-28	Bernstein Annual Strategic Decisions Conference	Conference
2026-05-28	Bernstein’s Annual Strategic Decisions Conference	Conference
2026-05-19	RBC Capital Markets Global Healthcare Conference	Conference
2026-05-12	BofA Securities Health Care Conference	Conference
2026-05-07	Gilead Sciences Q1 2026 Earnings Conference Call	Earnings call
2026-04-30	Annual Meeting Of Stockholders 2026	Shareholder meeting
2026-04-07	Gilead Sciences Update: Proposed Tubulis, Ouro, and Arcellx Acquisitions	Event
2026-03-11	Barclays Annual Global Healthcare Conference	Conference
2026-03-10	Leerink Partners Global Healthcare Conference	Conference
2026-03-03	TD Cowen Annual Health Care Conference	Conference
2026-02-10	Gilead Sciences Q4 2025 Earnings Conference Call	Earnings call
2026-01-12	J.P. Morgan Annual Healthcare Conference	Conference
2025-12-03	Annual Evercore Healthcare Conference	Conference
2025-12-02	Citi’s Global Healthcare Conference	Conference
2025-11-19	Jefferies Global Healthcare Conference in London	Conference
2025-11-10	UBS Global Healthcare Conference	Conference
2025-10-30	Gilead Sciences Q3 2025 Earnings Conference Call	Earnings call

Source: https://investors.gilead.com/overview/default.aspx

Key facts CIK 882095 CUSIP 375558103 13F (30d) 1875 filings 1781 filers Visit website Investor relations